Boehringer Ingelheim Venture Fund

Summary

Boehringer Ingelheim Venture Fund appeared to be the VC, which was created in 1973. The main office of represented VC is situated in the Ingelheim Am Rhein. The company was established in Europe in Germany. Boehringer Ingelheim Venture Fund appeared to be a CVC structure as part of the corporation.

The overall number of key employees were 7.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Boehringer Ingelheim Venture Fund, startups are often financed by High-Tech Gru00fcnderfonds, Forbion Capital Partners, BioMedPartners. The meaningful sponsors for the fund in investment in the same round are BioMedPartners, Forbion Capital Partners, Takeda Ventures. In the next rounds fund is usually obtained by High-Tech Gru00fcnderfonds, Forbion Capital Partners, BioMedPartners.

Deals in the range of 10 - 50 millions dollars are the general things for fund. Considering the real fund results, this VC is 27 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2016. The higher amount of exits for fund were in 2019. The fund is constantly included in 2-6 investment rounds annually. Opposing the other organizations, this Boehringer Ingelheim Venture Fund works on 12 percentage points less the average amount of lead investments.

Among the most popular fund investment industries, there are Therapeutics, Robotics. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Promethera Biosciences, Wellth, Tacalyx. The fund has no exact preference in some founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.